Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of caboza...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Runze, Song, Xinhua, Wang, Pan, Zhou, Yi, Lu, Xinjun, Wang, Jingxiao, Xu, Meng, Chen, Xinyan, Utpatel, Kirsten, Che, Li, Liang, Binyong, Cigliano, Antonio, Evert, Matthias, Calvisi, Diego F, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089119/
https://www.ncbi.nlm.nih.gov/pubmed/33144318
http://dx.doi.org/10.1136/gutjnl-2020-320716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089119/
https://www.ncbi.nlm.nih.gov/pubmed/33144318
http://dx.doi.org/10.1136/gutjnl-2020-320716

Ejemplares similares